)
Visual
test
Immunovant
Immunovant (IMVT) investor relations material
Immunovant Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Feb, 2026
Executive summary
Reported positive phase 2 results for brepocitinib in cutaneous sarcoidosis, with 100% of high-dose patients achieving clinically meaningful improvement and strong safety profile.
IMVT-1402 registrational trial in difficult-to-treat rheumatoid arthritis fully enrolled; topline data expected in H2 2026.
Multiple pipeline updates: NDA for brepocitinib in dermatomyositis submitted, phase 2B studies for IMVT-1402 in D2T-RA and mosliciguat in PH-ILD fully enrolled.
No product revenue to date; all activities are pre-commercial and centered on clinical development and regulatory progress.
$550 million raised in underwritten financing, extending cash runway to potential IMVT-1402 launch in Graves' disease.
Financial highlights
R&D expense for the quarter was $165M (GAAP), $147M (non-GAAP); G&A was $175M (GAAP), $71M (non-GAAP).
Net loss for Q3 FY2026 was $110.6M ($0.61 per share); non-GAAP net loss was $97.5M.
Cash and cash equivalents totaled $994.5M as of December 31, 2025, up from $714.0M at March 31, 2025, mainly due to a $550M equity raise.
Consolidated cash position remains strong at $4.5B, providing ample runway to profitability and flexibility for further investments.
Net loss for the nine months ended December 31, 2025 was $357.8M, up from $307.4M year-over-year.
Outlook and guidance
Pivotal phase 3 readout for brepocitinib in NIU expected in H2 2026; phase 3 in cutaneous sarcoidosis to start this year.
Topline data for IMVT-1402 in D2T RA and CLE expected in H2 2026; Graves' disease and MG data expected in 2027.
Existing cash is expected to fund operating expenses and capital requirements for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.
Multiple NDA and BLA filings anticipated, with several commercial launches possible in the next few years.
Anticipates continued net losses and significant R&D spending for the foreseeable future.
Brepo CS Phase III design considerations?
1402 D2T RA data: criteria for next study?
Capital allocation for internal vs. external R&D?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus.
Next Immunovant earnings date
Q4 202629 May, 2026
Immunovant
Next Immunovant earnings date
Q4 202629 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for patients with autoimmune diseases. Leveraging advanced anti-FcRn technology, Immunovant aims to create targeted therapies designed to address the complex and variable nature of autoimmune conditions. The company's approach is centered on improving the lives of patients by developing treatments that can potentially modify or halt the autoimmune response without compromising the immune system's ability to fight infections. Immunovant's research pipeline includes promising investigational products that embody the company's commitment to advancing the field of immunology and providing new options for individuals affected by autoimmune diseases. The company is headquartered in New York, NY, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage